REN and Hyperkalemia: One possible explanation is that spironolactone is frequently co-administered with renin–angiotensin system inhibitors such as ACEIs or ARBs, which collectively increase the risk of hyperkalaemia and may contribute to the higher observed incidence of DDIs.